Recombinant Human DLL4 Protein

Features and benefits
  • Expression System: HEK293
  • Protein Tag: C-His
  • Bioactivity: 1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DL
  • Endotoxin Concentration: <1.0 EU/μg
Item Number
rp181238
Grouped product items
SKUSizeAvailabilityPrice Qty
rp181238-10μg (Trial Size)
Apply for free trial size(?)
Every year, as a valued customer, you have the exclusive opportunity to explore and enjoy three different trial products of your choice, absolutely free!
10μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$99.90
rp181238-50μg
50μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$299.90
rp181238-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
rp181238-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,999.90

Animal Free, ≥95%(SDS-PAGE), Active, 293F cell, C-His tag, 1-524 aa

View related series
Accession#:Q9NR61 DLL4 Gene ID:54567

Basic Description

Product NameRecombinant Human DLL4 Protein
GradeActiBioPure™, Animal Free, Bioactive, Carrier Free
Product Description

Protein Function:
Delta-like protein 4 (DLL4) is a type I membrane protein belonging to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Notch signaling is an evolutionarily conserved pathway that controls cell fate and is required in multiple developmental processes including vascular development, hematopoiesis, somatogenesis, myogenesis, and neurogenesis. Dysregulation in the Notch pathway is associated with various human diseases. In mammals, four Notch homologs (Notch 1 to 4) and five ligands (DLL 1, 3 and 4, Jagged 1 and 2) have been identified. Notch ligands are transmembrane proteins with a DSL motif necessary for Notch binding, tandem EGF repeats, a transmembrane region and a short intracellular domain (ICD). Notch ligands are categorized into two subfamilies based on the presence of an extracellular cysteine-rich domain and insertions that interrupt some EGF repeats in the Jagged but not the Delta ligand family. Interactions of Notch receptors with their ligands result in reciprocal regulated intramembrane proteolysis (RIP). RIP is a mechanism for transmembrane signal transduction that involves the sequential processing by a disintegrin metalloprotease (ADAM) and then by presenilin/ gamma secretase, resulting in shedding of the extracellular domains and the generation of the soluble ICD signaling fragments, respectively. The Notch ICD translocates to the nucleus and interacts with transcriptional coactivators, resulting in the transcription of target genes. The ICDs of the Notch ligands have also been shown to translocate to the nucleus where they may have a signaling function. DLL4 is expressed highly and selectively within the arterial endothelium and has been shown to function as a ligand for Notch 1 and Notch 4. Human and mouse DLL4 share 86% amino acid sequence identity.

Specifications & PurityAnimal Free, Carrier Free, Bioactive, ActiBioPure™, ≥95%(SDS-PAGE)
Bioactivity1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DL
Endotoxin Concentration<1.0 EU/μg
Expression SystemHEK293
Amino Acids1-524 aa
SequenceMAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIP
Protein TagC-His
Predicted molecular weight55.7 kDa
SDS-PAGE55.7-64.8 kDa, under reducing condition; 56.6-68.7 kDa, under non-reducing condition

Images

Recombinant Human DLL4 Protein (rp181238) - ELISA
Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC ₅₀ of 69.79 ng/mL.

Recombinant Human DLL4 Protein (rp181238) - SDS-PAGE
2 μg/lane of Recombinant Human DLL4 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 55.7-64.8 kDa under reducing conditions and 56.6-68.7 kDa under non-reducing conditions.

Recombinant Human DLL4 Protein (rp181238) - Binding Activity
Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC₅₀ of 26.54 ng/mL.

Product Specifications

FormLyophilized
ReconstitutionWe recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.1 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilu
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -20°C for 1 year. Avoid freeze / thaw cycle.

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0606470Certificate of AnalysisJun 07, 2024 rp181238
ZJ24F0606469Certificate of AnalysisJun 07, 2024 rp181238
ZJ24F0606512Certificate of AnalysisJun 07, 2024 rp181238

Related Documents

Solution Calculators